Pronethalol hydrochloride  (Synonyms: (±)-Pronethalo hydrochloride)

Pronethalol ((±)-Pronethalo) is a non-selective β-adrenergic antagonist. Pronethalol is a potent inhibitor of Sox2 expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias, and limits the cerebral arteriovenous malformation (AVMs)^[1][2].

Pronethalol (2, 10, 20 μM) represses EGFP expression in a dose- and time-dependent manner in ReNcell VM cells. Pronethalol (10 μM; 2 days) reduces Sox2 expression to less than 10% after 2 days of treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pronethalol (0.15 mg/g; daily; for 14 days) stabilizes endothelial differentiation, lumen formation and improves cerebral arteriovenous malformation (AVMs) in Mgp^–/– mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

265.78

C₁₅H₂₀ClNO

51-02-5

OC(CNC(C)C)C1=CC=C2C=CC=CC2=C1.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71(4):503-8.  [Content Brief]

  [2]. Jiayi Yao, et al. Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. J Clin Invest. 2019 Jun 24;129(8):3121-3133.  [Content Brief]

  [3]. Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71(4):503-508.